Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Subclass of:

435 - Chemistry: molecular biology and microbiology

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435006000 Involving nucleic acid 4561
435700100 Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay 3840
435600100 Involving nucleic acid 2630
435029000 Involving viable micro-organism 1909
435005000 Involving virus or bacteriophage 1236
435018000 Involving hydrolase 554
435015000 Involving transferase 219
435025000 Involving oxidoreductase 176
435400500 Involving fixed or stabilized, nonliving microorganism, cell, or tissue (e.g., processes of staining, stabilizing, dehydrating, etc.; compositions used therefore, etc.) 160
435014000 Involving glucose or galactose 118
435008000 Involving luciferase 97
435013000 Involving blood clotting factor (e.g., involving thrombin, thromboplastin, fibrinogen, etc.) 87
435011000 Involving cholesterol 55
435010000 Involving uric acid 8
435012000 Involving urea or urease 7
435009000 Geomicrobiological testing (e.g., for petroleum, etc.) 1
20080311605KIT AND METHOD TO PERFORM A BIOLOGICAL TEST DESIGNED TO EVALUATE MINERALS POTENTIAL FOR BEING BIOLEACHED - A kit and method to perform a biological assay for evaluating the bioleaching potential of minerals, which allows to know the metallurgic response of minerals for geo-mining-metallurgic short and mid term planning, wherein the kit comprises a propylene tube-type container which has a line that specifies the liquid filling level, where is it possible to place a propylene sphere that floats at the liquid level and it has a plastic twist off cup on the upper extreme, while in the lower extreme or base there is a lyophilized biomass (powder) in charge of the mineral leaching.12-18-2008
20090081633Seed testing method and apparatus - A saturated cold germination test kit includes a compartment base, a lid and a holder for an oxygen scavenger. The base is water and airtight and includes a liquid gas exchange control trough around its perimeter. It is sized to house a high moisture holding seed planting surface pack at the bottom so seeds can be placed on top of the surface to imbibe and initiate pre-germination mechanisms. The lid has an edge that fits into a trough that houses a gas barrier liquid in the base to form an airtight seal and has an attachable compartment for an oxygen scavenger so the kit may be placed together in an airtight configuration with the oxygen scavenger inside to provide an anaerobic atmosphere for performing the saturated cold germination test in a cool location.03-26-2009
20100021881Peptide combos and their uses - The invention provides reagents and methods for the accurate quantification of proteins in complex biological samples. Quantification is obtained by adding to a sample a peptide combo, which is essentially a collection of synthetic reference peptides. The synthetic reference peptides have a small mass difference when compared to the biological reference peptides that originate upon digestion from the proteins present in the sample. Reference peptides and synthetic reference peptides are selected and the identity and accurate amounts of reference peptides are determined by mass spectrometry. The methods can be used in high throughput assays to interrogate proteomes.01-28-2010
20100055668Fluid-Transfer Collection Assembly Including Breakable Vial and Method of Using Same - A method of using a fluid transfer and mixing collection assembly includes depressing a flexible member to cause a force to be imparted to a breakable vial to break the vial, releasing the second fluid therein into an interior of the flexible member; releasing the flexible member to impart a negative pressure in the interior of the flexible member to draw a first fluid into the interior of the flexible member through the inlet check valve to mix with the second fluid; and depressing the flexible member to impart a positive pressure in the interior of the flexible member to pump the mixed first fluid and second fluid out of the interior of the flexible member through an outlet check valve and be transferred to test media.03-04-2010
20120183948Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties - Provided is a compound that comprises the structure:07-19-2012
20090087829PRODUCTION OF MONATIN ENANTIOMERS - Methods for preferentially hydrolyzing one stereoisomer of an isoxazoline diester over another, as well as an enzyme for facilitating the preferential hydrolysis are provided. Also provided are methods for providing mixtures of (RR) and (RS) monatin as well as (SS) and (SR) monatin, which methods can include the step of stereoselectively hydrolyzing an isoxazoline diester.04-02-2009
20100047762METHOD TO MONITOR DRUG EFFICACY IN DIABETIC PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL - HbA1c measurement is a critical component of diabetes management; however, a key limitation of HbA1c as a measure of glycemia is the lack of timeliness—it does not detect underlying blood glucose excursion levels in moderately controlled diabetic patients (HbA1c<8) as it is a measurement of mean glucose levels over the longer-term. HbA1c also averages both hypo- and hyperglycemia over two to three months; therefore, it does not adequately reflect improvements in post-prandial hyperglycemia. 1,5-AG is also a marker of glycemic control over a shorter one to two week timeframe, but with a different mechanism than HbA1c. Given the unique biological and physiological characteristics of 1,5-AG, it is sensitive to acute and transient episodes of hyper-glycemia and is, therefore, a better indicator of glucose excursions. Peptidyl diabetic drugs such as pramlintide and exenatide have unique mechanisms of action and the glycemic effects of these drugs are not adequately shown by HbA1c. 1,5-AG, an effective measure of glucose excursions, reveals underlying treatment effects of these drugs and can help regulate their dosage.02-25-2010
20100112544MODIFIED ROUTES OF LIPID METABOLISM, MEASURING OXIDIZED LDL AFTER FAT LOADING - The present invention relates to monitoring of lipid metabolism and is, particularly, directed to a test for estimating the individual susceptibility of a subject to the effect of oxidized dietary lipids. A high calorie and high fat meal were given to subjects and postprandial levels of oxidized low-density lipoproteins (LDL) were measured in the plasma of the subjects, indicating susceptibility to atherosclerotic events and insulin resistance. Food were also analysed for peroxide lipid content indicating LDL oxidizing potential of said foodstuff in a subject after consumption.05-06-2010
20100003664System for Glycated Protein Detection - A method of detecting the presence of glycated proteins or peptides (GPs) in a sample comprises carrying out the steps of assessing the sample for fluorescence, subjecting the sample to UV radiation, and reassessing the sample for an increase in fluorescence relative to any fluorescence assessed in said first assessing step, an increase in fluorescence at said reassessing step being indicative of the presence of GPs. The method may be useful for detecting disease such as diabetes.01-07-2010
20100075297PHOTOSENSITIVE POLYPEPTIDE AND METHODS OF THEIR PRODUCTION AND USE - Methods for producing polypeptides caged with a photolabile group on one or more backbone nitrogens are provided, in which the photolabile group is added to a growing polypeptide chain during polypeptide synthesis. Photosensitive polypeptides produced by the methods are described, as are methods of using such photosensitive polypeptides to assay enzyme activity or inhibit protein-protein interactions. Methods for producing polypeptides caged with a photolabile group on one or more side chain nitrogens, where the photolabile group is incorporated into the side chain during polypeptide synthesis, are also provided.03-25-2010
20090004641SITE-SPECIFIC LABELING OF AFFINITY PEPTIDES IN FUSION PROTEINS - The present invention provides methods and fluorescent compounds that facilitate detecting and labeling of a fusion protein by being capable of selectively binding to an affinity tag. The fluorescent compounds have the general formula A(B)n, wherein A is a fluorophore, B is a binding domain that is a charged chemical moiety, a protein or fragment thereof and n is an integer from 1-6 with the proviso that the protein or fragment thereof not be an antibody or generated from an antibody. The present invention provides specific fluorescent compounds and methods used to detect and label fusion proteins that contain a poly-histidine affinity tag. These compounds have the general formula A(L)m(B)n wherein A is a fluorophore, L is a linker, B is an acetic acid binding domain, m is an integer from 1 to 4 and n is an integer from 1 to 6. The acetic acid groups interact directly with the positively charged histidine residues of the affinity tag to effectively label and detect a fusion protein containing such an affinity tag when present in an acidic or neutral environment.01-01-2009
20090155767Methods for a predictive diagnostic test for tamoxifen - A method for determining the likelihood that a therapy involving administration of tamoxifen to a patient afflicted with an estrogen receptor positive breast cancer will provide a therapeutic benefit to the patient which comprises determining the level of expression of epidermal growth factor receptor present within a non-nuclear compartment in cells present in a breast tissue sample from the patient; and comparing the level of expression so obtained to a predetermined level of expression wherein the likelihood the therapy will provide a therapeutic benefit to the patient is greater if the level of expression in step a) is less than the predetermined level of expression.06-18-2009
20090155766Methods for detecting estrone by mass spectrometry - Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.06-18-2009
20090017442In-vitro diagnostic medical devices for determining saliva volume - The invention relates to a method of collecting saliva from the oral cavity for detecting a test substance, comprising the steps of (a) cleaning the oral cavity, (b) stimulating saliva secretion with a saliva-collecting solution, (c) removing the saliva-saliva collecting solution mixture from the oral cavity and collecting it in a container (01-15-2009
20100068695Inhibitor for enzyme having two divalent metal ions as active center - A pharmaceutical composition for use as an inhibitor of an enzyme having two divalent metal ions as an active center was found.03-18-2010
20090123908Collecting Device - A collecting device to be connected to at least one test tube, in which a sample is subjected to a wet combustion process, comprising a collector tube, which is arranged to collect and draw off from the test tube steam products from the wet combustion process. The collecting device further comprises at least one connecting tube, which has a first opening connecting the connecting tube to the collector tube and a second opening which is adapted to be inserted into the test tube. The collector tube comprises at least one projection extending from the interior of the collector tube to have a condensing sur-face for condensation of reagent in the steam products.05-14-2009
20130101984METHODS OF DETECTING SLEEPINESS - The present application is directed to methods of detecting sleepiness.04-25-2013
20110003277Dioxetane-Nanoparticle Assemblies For Energy Transfer Detection Systems, Methods Of Making The Assemblies, And Methods Of Using The Assemblies in Bioassays - Assemblies comprising nanoparticles and chemiluminescent substrates such as dioxetanes are provided. The assemblies can be used in assays to detect the presence and/or amount of a single analyte or multiple analytes in a sample. Methods of making the assemblies are also described.01-06-2011
20090305225Inhibition of Creatine Uptake to Promote Weight Loss - The present invention provides a method of promoting weight loss, or treating or preventing a body disorder related to excess weight, in a subject. The method comprises administering to the subject an effective amount of a creatine uptake inhibitor. Administration of the creatine uptake inhibitor is intracranial or directed to the hypothalamus. The invention further provides a method of screening for a novel compound that inhibits creatine uptake in the hypothalamus.12-10-2009
20090092959Nucleic acid and allergenic polypeptides encoded thereby in cashew nuts - The invention describes an isolated nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:1 or a degenerate variant of SEQ ID NO: 1. The nucleic acid sequence encodes an Ig-E binding immunogenic polypeptide the amino acid sequence of which comprises at least one sequence selected from SEQ ID NOS:4-25. The invention additionally provides an in vitro diagnostic test for detecting anti-cashew IgE in a patient. The test comprises reacting the patient's serum with a purified polypeptide the amino acid sequence of which comprises at least one sequence selected from SEQ ID NOS:3-25; separating the polypeptide from unreacted patient serum; reacting the polypeptide with a labeled human IgE-reactive agent after separating from unreacted patient serum; separating the polypeptide from unreacted labeled human IgE-reactive agent; and detecting labeled human IgE-reactive agent bound to the polypeptide after separating from unreacted agent to thereby indicate presence in the patient's serum of anti-cashew IgE.04-09-2009
20090011401GROUP OF REAGENT CARRIERS THAT IS COMBINED TO FORM A COMPOSITE - The invention concerns a group of reagent carriers that is combined to form a composite, each one of said carriers having at least one test region located in a shallow trough-like depression, where the reagent carriers in the composite are held together exclusively by interconnected protective covers for the test regions.01-08-2009
20090011400Substrate switched ammonia lyases and mutases - Crystal structure information is used to make substrate-switched amino acid ammonia lyase enzymes, including TALs, PALs and HALs. Related methods, systems, compositions, cells and transgenic organisms are provided.01-08-2009
20090208921METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES - The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry.08-20-2009
20080206737EXPRESSION QUANTIFICATION USING MASS SPECTROMETRY - In various aspects, the present teachings provide systems, methods, assays and kits for the absolute quantitation of protein expression. In various aspects, the present teachings provide methods of determining the concentration of about the top forty-one proteins present in human plasma. In various aspects, the present teachings provide methods of determining the absolute concentration of one or more proteins using standard samples of signature protein fragments and parent-daughter ion transition monitoring (PDITM). In various embodiments, the absolute concentration of multiple isoforms of a biomolecule in a sample, multiple proteins in a biological process, a combination of multiple samples, or combinations thereof, can be determined in a multiplex fashion using the present teachings. In various aspects, provided are methods of assessing the state of a biological system including, but not limited to, the disease state of an animal.08-28-2008
20110281257METHOD FOR PRODUCING BETA-SANTALENE - A method of producing β-santalene by contacting at least one polypeptide with farnesyl pyrophosphate (FPP). This method may be carried out in vitro or in vivo to produce β-santalene, a very useful compound in the fields of perfumery and flavoring. The present invention also provides the amino acid sequence of a polypeptide useful in the method of the invention. A nucleic acid encoding the polypeptide of the invention and an expression vector containing the nucleic acid are also disclosed, along with a non-human host organism or a cell transformed to be used in the method of producing β-santalene.11-17-2011
20110281256Systems and Methods of Detecting and Demonstrating Hair Damage Via Evaluation of Protein Fragments - Embodiments of a method for demonstrating type and/or source of hair damage comprises extracting protein fragments from a hair sample with an aqueous solution, testing the resulting protein fragments with the MALDI-MS test, and then either comparing the results between a damaged sample and an undamaged sample or comparing the results between a damaged sample and a list of known marker protein fragments to identify the type and/or source of the damage.11-17-2011
20110020784RED FLUORESCENT PROTEINS WITH ENHANCED BACTERIAL EXPRESSION, INCREASED BRIGHTNESS AND REDUCED AGGREGATION - Polynucleotides encoding variant polypeptides of DsRed are provided herein. The DsRed variants have increased bacterial expression, reduced aggregation, increased solubility, shifted emission spectra or increased brightness relative to a wild-type DsRed.01-27-2011
20090087830SYSTEMS AND METHODS FOR HARVESTING, STORING, AND IMPLANTING HAIR GRAFTS - A system and method for harvesting, storing, and implanting biological units, in particular hair follicular units (FUs). The system is particularly useful to facilitate hair transplant procedures. FUs are harvested from a body surface, either attached to a patient or in a strip of removed tissue, and shuttled into a cartridge having a plurality of receptacles. The receptacles are open in a distal direction toward a removal tool, but a cover over the proximal ends of the receptacles prevents the FUs from continuing out of the cartridge. The cover is made of a permissible medium, which may be fluid permeable and/or puncturable. One way to shuttle the FUs is to provide a pressure differential, such as by applying suction to the proximal end of a receptacle. The shuttle subsystem may be incorporated within an overall automated or robotic system, or the shuttle subsystem may form part of a semi-automated or even manual apparatus.04-02-2009
20120088225Method of Detecting Major In-Hospital Ischemic Complications and Predicting Length of Stay at an Intensive Care Unit - Methods of detecting major ischemic complications in critically ill patients comprise a) determining the blood concentration of glycerol at least once per hour; b) comparing the obtained blood concentration of glycerol with a defined critical level; and c) based on the comparison of step b), identifying patients experiencing or being at risk for major ischemic complications in order to select such patients for intensified surveillance and treatment. The methods allow early and reliable detection of major ischemic complications and identification of patients at risk for prolonged stay at an intensive care unit. The patients preferably have undergone surgical intervention with a following reperfusion or can be patients suffering from the complications of a trauma at an intensive care unit, or have undergone cardiac surgery.04-12-2012
20090208922FET BASED SENSOR FOR DETECTING BIOMOLECULE, METHOD FOR PREPARING THE SAME, AND METHOD FOR DETECTING BIOMOLECULE USING THE FET BASED SENSOR - Provided is a SWNT-FET-based sensor for detection of biomolecules including an increased Schottky contact area, a method for preparing the same, and a method for detection of biomolecules using the SWNT-FET-based sensor. According to the method of the present invention, a SWNT-FET-based sensor for detection of biomolecules having a thin and increased Schottky contact area can be obtained. The biomolecule detection sensor exhibits a superior detection sensitivity, and can effectively detect both nonspecific adsorption of biomolecules and specific biomolecule-biomolecule interactions, even at a low concentration of 1 pM, for example.08-20-2009
20100216115METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer.08-26-2010
20090042179Fluorescence Reflection Imaging Device with Two Wavelengths - A first light source has a first wavelength corresponding to an excitation wavelength of a fluorophore. The excitation wavelength and an emission wavelength of the fluorophore delineate a predetermined interval. A second light source has a second wavelength offset with respect to the first wavelength so as to be outside said predetermined interval. The offset between the first and second wavelengths is comprised between 30 nm and 100 nm. A camera comprises a filter opaque to the first and second wavelengths and transparent to the emission wavelength and to wavelengths substantially higher than the higher of the first and second wavelengths. The light sources and camera are synchronized to alternately activate one of the light sources and make the camera alternately acquire a fluorescence image and a background noise image.02-12-2009
20080206739Analysis Method for Pesticide Residues in Plant Samples - The invention relates to an analysis method for pesticide residues in plants. The method uses the interface device for the direct coupling of liquid chromatography and gas chromatography, called the TOTAD (Through Oven Transfer Adsorption Desorption) interface in scientific literature. The method only requires an extraction step prior to the chromatographic analysis. The pesticides are extracted from the sample with an organic solvent. Extract volumes that are much larger than those usually used are directly injected into the gas chromatograph, without needing any prior extract cleaning or concentration step. The TOTAD interface allows injecting extract volumes that are much larger than those normally injected into the gas chromatograph.08-28-2008
20090298047METHOD FOR DISTINGUISHING BETWEEN KIDNEY DYSFUNCTIONS - A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.12-03-2009
20090029344Compositions and assays utilizing ADP or phosphate for detecting protein modulators - Described herein are methods which identify candidate agents as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein. Generally, the methods involve the use of ADP or phosphate. The assays can be used in a high throughput system to obviate the cumbersome steps of using gels or radioactive materials.01-29-2009
20090263783NUCLEIC SEQUENCE AND DEDUCED PROTEIN SEQUENCE FAMILY WITH HUMAN ENDOGENOUS RETROVIRAL MOTIFS, AND THEIR USES - The present invention provides a translational product encoded by the nucleotide sequence of SEQ ID NO: 2, which corresponds to the gag gene of an endogenous human retrovirus named HERV-7q. The present invention also provides methods for diagnosing a neurological or autoimmune disease in a patient.10-22-2009
20090042180SYSTEM FOR SAMPLING AND TRACKING PLANT MATERIAL - A system and method for processing, i.e., sampling and tracking, plant material requires the ability to identify each plant in a plurality of plants. Initially, samples are taken from selected plants and are collected in respective storage locations in a magazine. During sampling, the identity of the plant source for each plant sample is stored. Further, the identity of each storage location receiving a plant sample is stored. Subsequently, the samples are transferred from the storage locations and are placed in respective wells of a receiving member for further downstream processing. Again, the identity of each well receiving a plant sample is stored. As a result, a plant sample in a well can be traced back to its plant source.02-12-2009
20100279269CHARACTERIZATION OF N-GLYCAN MIXTURES BY NUCLEAR MAGNETIC RESONANCE - The present disclosure provides nuclear magnetic resonance (NMR) methods for characterizing mixtures of N-linked glycans. Without limitation, methods of the present disclosure may be useful in characterizing monosaccharide composition, branching, fucosylation, sulfation, phosphorylation, sialylation linkages, presence of impurities and/or efficiency of a labeling procedure (e.g., labeling with a fluorophore such as 2-AB). In certain embodiments, the methods can be used quantitatively. In certain embodiments, the methods can be combined with enzymatic digestion to further characterize glycan mixtures.11-04-2010
20100143880ANALYSIS METHOD FOR DETERMINING A FUNCTIONAL PARAMETER OF AN ORGAN USING PREFERABLY AN AQUEOUS 13C-METHACETIN SOLUTION - The invention relates to an analysis method for determining a functional parameter of an organ of a human or animal individual by measuring the 06-10-2010
20110207114Amplified Fluorescence Polymers and Sensor Thereof - The present disclosure is related to amplified fluorescence polymers (AFPs) with pendant functional groups, their derivatives and their synthesis. The amplified fluorescence polymers can be used in various biological and chemical sensors.08-25-2011
20080241817Detection of NO By Using Guanylyl Cyclase and cGMP Production as a Readout System - The present invention relates to a method for determining NO enzymatically and its use for the identification of substances which can modulate a nitric oxide synthase activity.10-02-2008
20080274448Method for detecting a hydrophobic region of a target substance - An object of the present invention is to provides a method for detecting a hydrophobic region of a target substance that is capable of forming a hydrophobic region, such as a protein, which can detect a fluorescent analyte with high sensitivity with the use of a simple detection apparatus. The present invention provides a method for detecting a hydrophobic region of a target substance which comprises steps of allowing a target substance capable of forming a hydrophobic region to come into contact with a chemiluminescent substance, and assaying chemiluminescence.11-06-2008
20080286750APPARATUS INCLUDING ION TRANSPORT DETECTING STRUCTURES AND METHODS OF USE - The present invention recognizes that the determination of ion transport function or properties using direct detection methods, such as whole cell recording or single channel recording, are preferable to methods that utilize indirect detection methods, such as FRET based detection system. The present invention provides biochips and other fluidic components and methods of use that allow for the direct analysis of ion transport function or properties using microfabricated structures that can allow for automated detection of ion transport function or properties. These biochips and fluidic components and methods of use thereof are particularly appropriate for automating the detection of ion transport function or properties, particularly for screening purposes.11-20-2008
20080305469Fluorimetric Determination of Analytes By An Intramolecular Quencher-Fluorophore Conjugate - A method and reagent for detecting the presence or amount of an analyte by a redox reaction and a fluorimetric determination, is disclosed. The reagent comprises a compound of the general formula Q-F as a redox indicator, wherein Q is a quencher group and F is a fluorophore group. The quencher group Q or/and the fluorophore group F can be reduced or oxidized, and the fluorescence can change depending on the reduction or oxidation.12-11-2008
20080305468ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.12-11-2008
20080305467Generation Of Pulsating Pressure Waves, E.G. For Cell Lysis - The present invention relates to a method by which a controlled source of heat (preferably a laser 12-11-2008
20080206738Compositions and methods for modulating S-nitrosoglutathione reductase - Disclosed herein are methods and compositions for modulating the levels and/or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions.08-28-2008
20090317793MICROFLUIDIC DEVICE AND A MICROFLUIDIC SYSTEM AND A METHOD OF PERFORMING A TEST - A microfluidic device comprising at least one test channel, which test channel comprises an upper test channel section with an upstream end and a sampling region at its upstream end and at least one reference channel, which reference channel comprises an upper reference channel section with an upstream end and a sampling region at its upstream end. The test channel and the reference channel comprise a merging region downstream to the upper test channel section and a common downstream channel section. The merging region and the common downstream channel section are arranged such that a reference liquid flowing from the upper reference channel section into the merging region will block a test liquid flow in the upper test channel section when the test liquid flow has not yet reached the merging section. The microfluid device may be used for detecting change of flow properties e.g. due to agglomeration, agglutination or viscosity change in a liquid preferably selected from water, urine, blood, or blood plasma.12-24-2009
20080199849Method of Deriving Progenitor Cell Line - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.08-21-2008
20080268422Microbiological analysis assembly and method - The assembly comprises a filtration unit (10-30-2008
20100297601Small volume and ultra speed colorimetric sensor - A sensor designed to accommodate an aqueous analyte sample having a volume of less than 1 μL and can be used to quantify the amount and concentration of such analyte through light reflectance or fiber-optic light reflectance. The sensor includes a reaction membrane and a fixed-volume sample chamber. The fixed-volume sample chamber acts to collect the sample and to secure such sample while it undergoes detection. The reaction membrane contains all of the chemicals and enzymes needed to cause a color reaction when contacted with the sample. The amount of analyte can be determined by light reflectance intensity. The sensor can be used with a meter for in-vitro clinical diagnosis and for patient self-monitoring of a physical condition, such as blood glucose levels.11-25-2010
20110207113PROTEIN STRUCTURE AND METHOD OF USING PROTEIN STRUCTURE - Methods for building an atomic model of a protein molecule that include: (a) identifying a protein molecule with at least 20% sequence identity to Microsomal Prostaglandin E Synthase 1 (MPGES1) and (b) utilizing the atomic coordinates of MPGES1 to obtain an atomic model of the identified protein molecule are provided. Methods for determining a drug candidate compound that interacts with members of the MAPEG family, in particular MPGES1, are also provided.08-25-2011
20100151440HIGH THROUGHPUT SCREENING PLATFORM FOR HIGH ETHANOL - Provided herein are high throughput methods for converting starch-containing plant material to ethanol, wherein the conversion process is performed at a small scale. This high-throughput screening platform permits the evaluation of the ethanol obtained from starch-containing plant material in a rapid and efficient manner. The methods include obtaining a plurality of samples of starch-containing plant material and drying the samples to achieve a desired moisture level. The dried samples are liquefied under conditions sufficient to hydrolyze the starch-containing plant material to soluble dextrinized substrates. The liquefied samples are fermented in small volume headspace vials for a period of less than about 96 hours, and fermentation is terminated by pasteurization. Ethanol production is evaluated using headspace gas chromatography.06-17-2010
20090004642In vitro Method for the Determination of Glycemic Index of Food Products - The present invention provides an in vitro method for determining the glycemic index values for various food products. The present invention provides an accurate and inexpensive in vitro method for determining the glycemic index of a wide variety of both food ingredients and finished food products.01-01-2009
20090081634FLUORESCENT AND SACCHARIDIC SUBSTRATES, THEIR PROCESS OF PREPARATION AND THEIR USE - The present invention relates to fluorescent enzymatic substrates of saccharidic nature having a self-cleavable spacer arm functionalized by a fluorophore F and by at least one inhibitor of the fluorescence of F, to the use thereof for preparation of a diagnostic reagent for functional imaging in vivo, and to the diagnostic reagent for functional imaging containing at least one such enzymatic substrate.03-26-2009
20090081635MODIFIED HEPARINASE III AND METHODS OF SEQUENCING THEREWITH - The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.03-26-2009
20090197242Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease - The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.08-06-2009
20090117534COMPOSITIONS AND ASSAYS UTILIZING ADP OR PHOSPHATE FOR DETECTING PROTEIN MODULATORS - Described herein are methods which identify candidate agents as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein. Generally, the methods involve the use of ADP or phosphate. The assays can be used in a high throughput system to obviate the cumbersome steps of using gels or radioactive materials.05-07-2009
20090208923System and method for diagnosing diseases - One aspect of the invention provides a method of diagnosing a disease condition, comprising measuring presence or amount of a targeted protein or a degradation product of said protein in a collected biological sample as a marker for the disease condition. The targeted protein or degradation product is selected for measurement based on a prior identification of a measurable half-life at a predetermined time period, including the time at which said method is conducted, and correlating said measuring with the presence or absence of the disease condition. The targeted protein or degradation product may be identified by selecting a protein known or suspected to be a diagnostic marker for the disease condition, analyzing degradation of the protein in the collected biological sample, and selecting a protein or degradation product that exhibits a measurable half-life at a predetermined period of time. The analyzing may include identifying degradation product(s) of the protein as a function of time, and half-life of the protein and the degradation product(s).08-20-2009
20090215024BIOMARKERS UPREGULATED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer.08-27-2009
20080261196NAPHTHALENE DIIMIDE-ZN(II) COMPLEX HAVING SELECTIVITY FOR PYROPHOSPHATE, PREPARATION METHOD THEREOF AND DETECTING METHOD OF PYROPHOSPHATE USING THE SAME - The present invention provides a novel fluorescent chemosensor including a naphthalene diimide-Zn(II) complex, which can efficiently recognize pyrophosphate (PPi) at pH 7.4. The fluorescent chemosensor exhibits a new kind of excimer fluorescence, which is selective for PPi in 100% aqueous solution. Further, since the naphthalene diimide-Zn(II) complex of the present invention does not couple with inorganic phosphate (Pi) or adenosine triphosphate (ATP) and has high selectivity for PPi, it can be usefully used to detect pyrophosphate (PPi), which serves to transfer signals and store energy in living organisms.10-23-2008
20090253116METABOLIC SYNDROME EVALUATING APPARATUS, METHOD, SYSTEM, PROGRAM, AND RECORDING MEDIUM THEREFOR - According to the method of evaluating metabolic syndrome, amino acid concentration data on the concentration value of amino acid in blood collected from a subject to be evaluated is measured, and the state of metabolic syndrome in the subject is evaluated based on the measured amino acid concentration data of the subject.10-08-2009
20090220936Flow Cytometry Reagent System - A method of measuring cellular hemoglobin of a blood sample includes mixing a blood sample with a permeation reagent, and incubating the sample mixture to permeate cellular membrane of red blood cells and to cause hemoglobin aggregation within the cells; adding a neutralization reagent to inhibit further reactions of the permeation reagent; performing a cell-by-cell measurement of side scatter signals of the red blood cells in the sample mixture on a flow cytometer; and obtaining cellular hemoglobin (Hgb09-03-2009
20090253117ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS - An inventive substrate is provided which includes a substrate compound of formula A-B10-08-2009
20090142746Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.06-04-2009
20080311555In Vitro Root-Nematode Assay in Multi-Well Plates - The invention provides an improvement in the method of screening roots, both transgenic and non-transgenic, for activity against parasitic nematodes. In particular, the improvement of the invention is use of multi-well cell culture plates for root culture and nematode infection steps.12-18-2008
20090317791Methods and apparatus for performing retention-time matching12-24-2009
20090275012Process For Determining S-Nitrosothiols In Biological Fluids - A process for determining S-nitrosothiols, in particular S-nitrosoglutathione, in biological fluids that is easy, selective, cheap with respect to the prior art, which requires the use of equipment commonly available in laboratories, at low cost, which can be used by not qualified operators. The process is based on the hydrolysis of S-nitrosoglutathione (GSNO) by an enzyme, in particular γ-glutamyltranspeptidase (GGT). This enzyme hydrolizes the residual 7-glutamyl of GSNO for giving glutamate (GIu) and S-nitroso-cysteinylglycine (GIyCySNO). In the presence of ions of transition metals GGT speeds up the release of NO since the intermediate that is formed, the GIyCySNO, is is much more sensitive to a metal-dependent decomposition. Advantageously, the amount of nitric oxide present in the sample is measured through a reaction thereof with 4,5 diaminof luorescein (DAF-2), said reaction creating a fluorescent compound in an amount proportional to the S-nitrosothiol amount present in the sample. Alternatively, the amount of released NO can be measured by a chemiluminescence analyser, commercially available. In the presence of biological fluids having complex matrix, the introduction of the enzyme is done after separation of the S-nitrosothiol from the other components of the fluid.11-05-2009
20100184013DETECTION OF OLIGOSACCHARIDES - Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.07-22-2010
20100190146Microfluidic Glycan Analysis - Microfluidic devices and methods for analyzing glycan profiles of glycoproteins are provided. Some embodiments of the devices comprise a deglycosylation column for cleaving glycans, an optional cleaning column for removing proteins, a trapping column for enriching glycans, and a separation column for resolving glycans. The devices and methods significantly improve the speed and sensitivity of glycan analysis.07-29-2010
20090298046Assays for Histone Deacetylase 1/2 Selective Inhibitors - The present invention relates to an assay specific for histone deacetylases HDAC1 and/or 2 inhibitors which comprises: (i) incubating an HDAC1 and/or 2 enzymes(s) together with a protein that contains the SANT and ELM2 regions, found in MTA proteins such as MTA-2, MTA-1, MTA-3 and also found in CoREST, CoREST2, CoREST3 and MI-ER1, in a suitable assay buffer (ii) adding the potential HDAC inhibitor and a suitable substrate and incubating (iii) stopping the incubation and determining the effect the putative HDAC inhibitor has had on enzyme activity by comparison with standards.12-03-2009
20100216113Methods - A method for selecting or designing a compound expected to modulate the activity of Leukotriene C4 synthase (LTC4S), the method comprising the step of using molecular modelling means to select or design a compound that is predicted to interact with the catalytic site or a substrate binding region of LTC4S, wherein a three-dimensional structure of at least a part of the catalytic site or a substrate binding region of LTC4S is compared with a three-dimensional structure of a compound, and a compound that is predicted to interact with the said catalytic site or substrate binding region is selected. The selected compound may be predicted to bind to at least a part of a region of the structure termed the “GSH substrate binding cavity” (formed by residues including residues Arg51, Arg30, Arg104, Gln53, Asn55, Glu58, Tyr59, Tyr93, Tyr97, Ile27, Pro37, Leu108 of full length human LTC4S, or equivalent residues); the “lipophilic substrate binding crevice” (formed by residues including Ala20, Leu24, Ile27, Tyr59, Trp116, Ala112, Leu115, Leu108, Tyr109, Leu62, Val119, Thr66, Vall6 and Leu17, or equivalent residues); or the “catalytic site” (formed by residues including Arg104 or Arg31, or equivalent residues).08-26-2010
20100151439Enzymatic Assays for a Droplet Actuator - A method of conducting a droplet-based enzymatic assay is provided. The method generally makes use of a droplet actuator. A droplet comprising an enzyme of interest is provided on the droplet actuator along with a droplet comprising a substrate which is potentially modified in the presence of the enzyme. The method involves executing droplet operations on the droplet actuator to combine the droplets, thereby yielding an assay droplet, and detecting modification of the substrate by the enzyme in the assay droplet on the droplet actuator. The enzyme of interest may, for example, be a potentially mutated or improperly folded enzyme exhibiting altered enzyme activity as compared to a corresponding normal enzyme.06-17-2010
20100216112Crystal structures of both isoforms of human glutamic acid decarboxylase - A crystal comprising an isoform of an N-terminal truncation of GAD chosen from the group consisting of a monoclinic P208-26-2010
20100216114METHOD AND APPARATUS FOR DETERMINATION OF COMPONENTS IN ROOT CROPS - The invention relates to a process for the determination of components in root crops as well as a device for performing the process. Root crops of a plot are prepared in such a way that becomes possible, using near-infrared spectroscopy, to determine the content of substances with a high analytical accuracy and short analysis time and wherein the recorded data concerning the identity and quantity of ingredients are representative of all root crops of a plot.08-26-2010
20100227308INFORMATION ACQUISITION METHOD, INFORMATION ACQUISITION APPARATUS AND DISEASE DIAGNOSIS METHOD - An information acquisition method for acquiring information on a target object, that includes a step of promoting ionization of the target object using a substance for promoting ionization of the target object to cause the target object to emit, and a step of acquiring information on the mass of the flew target object using time-of-flight secondary ion mass spectrometry.09-09-2010
20100227309METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS - A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholestrols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers.09-09-2010
20100240022Reagent preparation and valving design for liquid testing - The technology described in this disclosure is a combination of controlled and precise ‘reagent delivery’ integrated together with controlled liquid flow through a sample processing device used for generating a desired chemical or biological reaction.09-23-2010
20080274447Method and Apparatus for Implementing Threshold Based Correction Functions for Biosensors - A biosensor system, method and apparatus are provided for implementing threshold based correction functions for biosensors. A primary measurement of an analyte value is obtained. A secondary measurement of a secondary effect is obtained and is compared with a threshold value. A correction function is identified responsive to the compared values. The correction function is applied to the primary measurement of the analyte value to provide a corrected analyte value. The correction method uses correction curves that are provided to correct for an interference effect. The correction curves can be linear or non-linear. The correction method provides different correction functions above and below the threshold value. The correction functions may be dependent or independent of the primary measurement that is being corrected. The correction functions may be either linear or nonlinear.11-06-2008
20080227082METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE - Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.09-18-2008
20090068634SUBSTRATES AND INTERNAL STANDARDS FOR MASS SPECTROMETRY DETECTION - An inventive substrate is provided which includes a substrate compound of formula A-B03-12-2009
20090035746Device and Method for Preparing a Sample for an Analysis and Device and Method for Analyzing a Sample - A device and method are disclosed for preparing a sample for an analysis and a device and method are disclosed for analyzing a sample. In at least one embodiment, a device is disclosed for preparing a sample for analysis including means for binding at lest one biological structure of the sample, means for releasing at least one biological molecule contained in the at least one structure, and means for binding the at least one released molecule. The means for binding the at least one structure and the means for binding the at least one molecule can move.02-05-2009
20100178648IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS - Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.07-15-2010
20110236877BIOSENSOR AND METHOD USING THE SAME TO PERFORM A BIOTEST - The present invention discloses a biosensor and a method using the same to perform a biotest. The biosensor of the present invention integrates a SAW (Surface Acoustic Wave) device and a test polymer to detect an analyte in a liquid specimen. The test polymer reacts with the analyte. After reaction, the substantial weight decrease of the test polymer causes the variation of the SAW characteristics. The attributes and content of the analyte is detected and determined according to the variation of the SAW characteristics.09-29-2011
20100055664ENCLOSED MEMBRANE-CLAMPING DEVICES FOR RUNNING BIOLOGICAL ASSAYS ON MEMBRANE SURFACES - An enclosed membrane-clamping (EMC) device is disclosed for running biological assays on membrane surfaces, such as Western blotting. The EMC device comprises a cover plate and a support plate, which can be coupled through a sealing mechanism. The cover plate, the support plate and the sealing mechanism are shaped such that their inner surfaces form one or more enclosed chambers. When in use, a blotting membrane is placed between the cover plate and the support plate, and clamped in the chamber formed in the EMC device. The EMC device is coupled with an assisting device to realize automation of manipulations. Liquid-phase target solutions are introduced into the chamber through its inlet and outlet to realize surface-molecular interactions between the target on the blotting membrane and the targets introduced in liquid phase. The chamber with a small vertical dimension is capable of achieving the blotting assays at a higher speed.03-04-2010
20120244520D-SERINE DEHYDRATASE AND USE THEREOF - A novel D-serine quantification method that can overcome various disadvantages of a conventional D-serine quantification method; a novel enzyme that can be used in the D-serine quantification method; a gene encoding the enzyme; and the like. Specifically, a novel D-serine dehydratase including (a) a protein having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a protein having an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 1 and having a D-serine dehydratase activity; and a D-serine quantification method including the steps of reacting a sample with the enzyme, quantifying ammonia or pyruvic acid produced by the reaction, and calculating the amount of D-serine in the sample based on a value produced by the quantification.09-27-2012
20100062414SAMPLE LIQUID ANALYTICAL CHIP - A sample liquid analytical chip that whilst being of simple structure, has a reaction region and a detection region isolated from each other and further has liquid feed control means for a sample liquid, thereby realizing speedy reliable analysis. The sample liquid analytical chip comprises a tubular sample liquid transfer channel with its both ends open, a reaction reagent layer disposed on the internal wall surface of the sample liquid transfer channel and a detection region for detecting any physical or chemical change of the sample liquid. In the sample liquid analytical chip, the sample liquid transfer channel at an area of its wall surface is provided an opening and a lid fitted to the opening. Portion of the lid forms a hinge in cooperation with the wall surface.03-11-2010
20100055667Restricted Access Media and Methods for Making Restricted Access Media - The present invention is directed to restricted access media (RAM), methods for preparing restricted access media, and kits for preparing restricted access media that contain protected ligand binding agents or protected enzymes. Certain RAM provided contain a plurality of protected regions of the support that contain ligand binding agents that are protected by blocking agents. Certain RAM provided contain a plurality of protected regions of the support that contain unbound ligand binding agents or enzymes that are retained in the protected regions by a capping agent. Methods of making the RAM of the invention and associated kits are also provided03-04-2010
20100055666BIOSENSOR WITH EVANESCENT WAVEGUIDE AND INTEGRATED SENSOR - The present invention is directed to a waveguide sensor as well as to an evanescent field induced evanescent field induced sensor system for use in diagnostic housing and an integrated waveguide sensor comprising: a waveguide layer,—capture compounds applied on the upper surface of said waveguide layer for 03-04-2010
20090029343Methods for isolation and analysis of sialylated and phosphorylated peptides - Changes in sialylation of cell surface or plasma proteins are often associated with various cancers and other disease conditions Provided are methods of detecting biomarkers of conditions associated with a change of sialylation status. Sialylated peptides are first isolated from biological and other samples by loading onto titanium dioxide (TiO2) or zirconium dioxide (ZrO2) stationary phase under acidic conditions in a solution comprising at least 20% organic phase and at least about 6.5 mM of substituted aromatic carboxylic acid, or, alternatively, at least about 1 mM short chain, non-aromatic, hydroxylated carboxylic acid. Sialic acid containing proteins can then be eluted from loaded stationary phase material by exposure to an alkaline solution having pH of 9.0 or greater, preferably at least 10.5. Sialylated peptides isolated by the methods provided can then be analysed by mass spectrometry to identify patterns of sialylation across a sialiome (the entire complement of sialic acid containing peptides in a biological sample) and/or to identify proteins in a sample that are sialylated or that show changes in sialylation status between two or more different samples. In preferred embodiments, sialylated peptides from control and patient samples can be differentially isotopically labelled and compared in a single mass sprectrometry experiment. Also provided are specific biomarkers of bladder cancer. The methods for isolating and analysing sialylated proteins can also by applied to phosphorylated proteins.01-29-2009
20090215026METHOD FOR STORING TETRAZOLIUM COMPOUND, STABILIZER USED IN THE SAME, AND TETRAZOLIUM COMPOUND REAGENT SOLUTION USING THE METHOD - A method for storing a tetrazolium compound stably is provided. The tetrazolium compound is stored in the presence of sodium azide. The tetrazolium compound (A) and the sodium azide (B) are present at a ratio (A:B) in the range from 1:0.02 to 1:6.2. Furthermore, when the tetrazolium compound is stored as a solution, the concentration of the sodium azide is in the range from 0.08 to 3.2 mmol/L and the concentration of the tetrazolium compound is in the range from 0.5 to 8 mmol/L. As the tetrazolium compound, it is preferable to use 2-(4-iodophenyl)-3-(2,4-dinitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium salt.08-27-2009
20090215023HIGH TEMPERATURE FLOW-THROUGH DEVICE FOR RAPID SOLUBILIZATION AND ANALYSIS - Devices and methods for thermally lysing of biological material, for example vegetative bacterial cells and bacterial spores, are provided. Hot solution methods for solubilizing bacterial spores are described. Systems for direct analysis are disclosed including thermal lysers coupled to sample preparation stations. Integrated systems capable of performing sample lysis, labeling and protein fingerprint analysis of biological material, for example, vegetative bacterial cells, bacterial spores and viruses are provided.08-27-2009
20110081641Method and Apparatus for Automating Chemical and Biological Assays - A device which collects specimen fluids or performs chemical or biological assays of the specimen fluid is provided with a specimen fluid receiver and a fluid actuated trigger coupled to receive specimen fluid from the specimen fluid receiver. The trigger is made of a material which expands substantially upon absorbing specimen fluid, and it is mounted and positioned so as to contact and move another component of the device upon expanding through the absorption of specimen fluid. Preferably, the trigger is mounted to the other component and is positioned to press against a stationary surface upon expanding, so that the trigger causes the other component to move. Also, the other component may contain a surface coupled to receive specimen fluid from the specimen fluid receiver and the surface has an area which contains a substance which interacts with the specimen fluid. The trigger is coupled to receive specimen fluid from the specimen fluid receiver in such a manner that there is a predetermined delay before the trigger expands sufficiently to move the other component, and the specimen fluid interacts with the substance during delay.04-07-2011
20110065085NOVEL HEPARIN ENTITIES AND METHODS OF USE - The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.03-17-2011
20100279270PROCESS FOR PRODUCTION AND QUANTITATION OF HIGH YIELD OF BIOBUTANOL - The present invention provides a process for production of high yields of butanol by 11-04-2010
20080199847Method for Predicting the Metabolism of Drug in Human Liver and Liver Function - The invention provides a method for precisely predicting the metabolism of a drug in human liver and the effect of the drug on liver function. The invention provides a method for predicting a metabolite of a test substance produced in human liver and functions of the liver, wherein the method includes administering a test substance to a nonhuman chimeric animal and a non-chimeric animal of the same species, wherein the chimeric animal intracorporeally carries a population of human-origin hepatocytes having proliferation potential and in which the hepatocyte, population substantially functions as the liver of the chimeric animal, and wherein these animals are protected from the attack by a human complement produced by the hepatocytes; and analyzing and comparing metabolites from the chimeric animal and the non-chimeric animal.08-21-2008
20080248458Purification, Characterization and Reconstitution of a Ubiquitin E3 Ligase - The present invention provides a native or reconstituted complex comprising Bmi1 and/or Ring1 and/or Ring2, wherein the complex has ubiquitin E3 ligase activity. Optionally, the complex further comprises HPH2 and/or HPC3. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that modulate the ubiquitin E3 ligase activity of the native or reconstituted complex, and methods of identifying candidate compounds for treating cancer. Kits for determining modulation of protein ubiquitination and/or for ubiquitinating a target substrate are further provided.10-09-2008
20080248457Sensor Chip and Manufacturing Method Thereof - Provided are a sensor chip and a manufacturing method of this sensor chip, that includes a substrate, a cover layer, a spacer layer sandwiched between the substrate and the cover layer, and a hollow reaction section between the substrate and the cover layer, wherein warping due to changes in the environmental temperature and humidity does not occur.10-09-2008
20090317792OIL EMULSIONS AND METHODS FOR MANUFACTURE AND USE THEREOF - The invention provides oil emulsion droplets and a general and facile method for providing same through the use of templating multilayer capsules. The oil emulsion droplets are further useful in fabricating liquid crystal droplet-based biosensors for the detection of target analytes such as bacteria or viruses in a sample.12-24-2009
20090226884Method of Quantitative Analysis of Oxidized Protein, Labeling Reagents for Quantitative Analysis of Oxidized Protein and Labeling Reagent kit for Quantitative Analysis of Oxidized Protein - Oxidized proteins, which have undergone oxidative modifications, are labeled with labeling reagents and quantified by mass spectrometry. In this process, a first labeling reagent, which is capable of reacting with the oxidized proteins, and a second labeling reagent, which has the same chemical structure as the first labeling reagent and in which at least part of the component atoms is substituted by an isotope of the atom concerned, are employed as the labeling reagents. The oxidized proteins labeled with the first labeling reagent and the oxidized proteins labeled with the second labeling reagent are mixed together and subjected to mass spectrometry, with mixing ratios varied. As the labeling reagents, are raised here 2,4-dinitrophenylhydrazine and 2,4-dinitrophenylhydrazine in which a carbon atom on the phenyl group has been substituted by a stable isotope (09-10-2009
20120202188SERUM-BASED BIOMARKERS OF PANCREATIC CANCER AND USES THEREOF FOR DISEASE DETECTION AND DIAGNOSIS - Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.08-09-2012
20110177490LIQUID FOR DISCHARGE, METHOD FOR DISCHARGING BIOSPECIMEN, AND COMPOUND - A liquid for discharge includes: a biospecimen; and at least one kind of compounds represented by the formula (1).07-21-2011
20090017441ASYMMETRIC CYANINE FLUORESCENT DYES - The present disclosure provides the asymmetric cyanine fluorescent dyes of formula I in which X, n, R01-15-2009
20110177491PEPTIDE FOR USE IN SIMULTANEOUS PROTEIN QUANTIFICATION OF METABOLIZING ENZYMES USING MASS SPECTROMETRIC ANALYSIS APPARATUS - There are provided a peptide consisting of an amino acid sequence for simultaneously quantifying absolute amounts of metabolizing enzyme proteins in a biological sample at high sensitivity and a method for using the same. A peptide which can be detected at high sensitivity with a mass spectrometer that enables highly sensitive simultaneous quantification of metabolizing enzymes, intracellular proteins, is selected, and the amino acid sequence thereof is identified. Using a stable-isotope-labeled peptide having the same amino acid sequence as the amino acid sequence of this peptide to be quantified, a mass spectrometry by LC-MS/MS is performed at predetermined concentration levels of the stable-isotope-labeled peptide to create a calibration curve. The stable-isotope-labeled peptide is added to a peptide fragment obtained by fragmenting metabolizing enzyme proteins to be quantified in a sample with trypsin, amass spectrometry by LC-MS/MS is performed to calculate amass spectrum area ratio of the metabolizing enzyme protein peptides to be quantified and the stable-isotope-labeled peptide, and a quantitative value is obtained from the area ratio using the calibration curve.07-21-2011
20080227083OPTICAL DETECTOR FOR ENZYME ACTIVATION - Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes—a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy, at the second and third wavelengths.09-18-2008
20080213745Biomarkers Of Metabolic Responses To Hepatotoxicants And Carcinogens - Methods for the measurement and prediction of response to hepatotoxicants and carcinogens through the detection of metabolites in a mammal are provided. The metabolites can be used as biomarkers, including efficacy biomarkers, surrogate biomarkers, and toxicity biomarkers. The methods find use for early prediction of toxicity, target identification/validation, and monitoring of drug efficacy.09-04-2008
20080213746Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin - The invention provides methods for the diagnosis and risk stratification of adverse events in post-myocardial infarction patients by means of proADM, whereby a determination of the marker pro-adrenomedullin or partial sequence or a fragment thereof or contained in a marker combination (panel, cluster) is carried out on a post-myocardial infarction patient. The invention also provides a diagnostic device and a kit for the performance of the method of the method of the invention.09-04-2008
20110053137METHODS OF MODULATING COLD SENSORY PERCEPTION - The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.03-03-2011
20080233555HOMOGENEOUS ASSAY FOR ENZYMATIC ACTIVITY - An assay is disclosed for measuring activity of enzymes, such as kinases, phosphatases, and proteses. Measurements of enzymatic activity are accomplished in a homogenous assay format utilizing a fluorescence quenching technique employing paramagnetic metal ions.09-25-2008
20110136097METHOD FOR DETERMINING ORIGIN OF ALCOHOL OR SUGAR CONTAINING PRODUCTS - A method for determining origins of food products, and more specifically for determining geographic and/or biological origin of food products containing alcohols or sugars includes preparing an alcohol sample from a product in question, removing exchangeable hydrogen/deuterium atoms from alcohol molecules of the sample, determining the isotopic composition of non-exchangeable hydrogen/deuterium atoms from sample alcohol, and analyzing results for adulteration or determination of product origin. In addition, alcohol δ06-09-2011
20100311037MALONATE DECARBOXYLASES FOR INDUSTRIAL APPLICATIONS - The present invention relates to a method for the enzymatic decarboxylation of malonic acid (propanedioic acid) derivatives catalyzed by enzymes structurally and/or functionally related to arylmalonate decarboxylase (AMDase) as isolated from microorganisms of the genus 12-09-2010
20100167263NOVEL BIOSENSOR SYSTEM BASED ON RECOGNITION INDUCED BIREFRINGENCE (RIB) - The present invention relates to a label-free biosensor system, a method for manufacturing said label-free biosensor system, its use for detecting biochemical reactions and/or bindings, enzymatic reactions, nucleic acid hybridizations, protein-protein interactions and protein-ligand interactions, as well as an assay method for detecting and/or quantifying an analyte of interest in a biological sample which comprises detecting the Recognition Induced Birefringence (RIB) generated in the presence as opposed to the absence of said analyte by bringing said sample into contact with said label-free biosensor system.07-01-2010
20100068694METHOD, REAGENT AND KIT FOR MALARIA TESTING - The present invention provides a method for malaria testing which enables testing for the presence of malaria infection and the extent of the infection in a convenient manner; and a reagent or kit which can be used in the method. The method for malaria testing according to the present invention includes the step of detecting a liver-type fatty acid binding protein present in urine collected from a subject animal. The extent of infection is determined to be higher when a larger amount of the liver-type fatty acid binding protein is present in a test sample.03-18-2010
20090117535Method for identifying HIV-1 protease inhibitors with reduced metabolic affects - The invention provides a novel in vitro method for identifying HIV-1 protease inhibitors with reduced potential for inducing metabolic abnormalities. The invention further provides diagnostic methods for identifying patients who may be at risk of developing metabolic abnormalities subsequent to the administration of an HIV-1 protease inhibitor. The invention also provides novel polynucleotides associated with the incidence of HIV-1 protease inhibitor induced metabolic abnormalities. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. The invention further relates to diagnostic methods for using these novel polynucleotides in the diagnosis, treatment, and/or prevention of HIV-1 protease inhibitor induced metabolic abnormalities.05-07-2009
20100009337NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC, and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.01-14-2010
20100105023In Vitro Method Modeling The Consistency Generated In Vivo By Food During The Digestion Thereof - The present invention relates to an in vitro method modeling and measuring the consistency generated in vivo by a food during the digestion thereof, comprising the following steps: 04-29-2010
20090075249Engineering beta-ketoacyl ACP synthase for novel substrate specificity - Methods of altering substrate specificity of beta-ketoacyl-ACP synthase, and engineered beta-ketoacyl-ACP synthases so produced are provided. DNA sequences and constructs for expression of engineered beta-ketoacyl-ACP synthases, as well as the novel beta-ketoacyl-ACP synthases produced therefrom are also provided. Such DNA sequences may be used for expression of the engineered beta-ketoacyl-ACP synthases in host cells, particularly seed cells of oilseed crop plants, for the modification of fatty acid composition.03-19-2009
20090239210Proteins recruited by virus during infection of plants and method for their isolation and identification - The invention relates to a method for isolating and identifying proteins from protein-virus complexes and comprises: —the gel exclusion chromatography of virus-protein complexes extracted from infected plants or such as obtained by adding a purified virus to soluble proteins extracted from non infected plants, —SDS-PAGE of the proteins-analysis by NanoLC-MS/MS after tryptic digestion and protein identification.09-24-2009
20100167262METHOD AND REAGENT FOR THE SPECIFIC IDENTIFICATION AND QUANTIFICATION OF ONE OR MORE PROTEINS IN A SAMPLE USING IN PARTICULAR INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY - The invention relates to a method for the identification and quantification of one or more biomolecules in a sample containing a mixture of substances, wherein said method comprises the steps of, a) providing a sample which contains one or more biomolecules, b) providing a reagent for the analysis of biomolecules according to Formula I (A-Y-PRG) wherein, A may be present or absent and when A is present, A is H or constitutes at least one functional group for the reversible, covalent or non-covalent binding to a support material, whereby Y is a group comprising at least one chelate function for metals, preferable low in isotopes, and whereby PRG is a reactive group for the selective binding of biomolecules to be analyzed, c) coupling the one or more biomolecules from step a) to the reagent of step b), d) selecting the one or more biomolecules labeled in step c) under the employment of a functional group for the reversible, covalent or non-covalent binding to a support material and removal of the one or more unbound biomolecules, wherein (d) optionally comprises releasing the bound biomolecules from the support material and the elution from the matrix; and f) detecting and identifying the one or more labeled biomolecules by means of Inductively Coupled Plasma-Mass Spectrometry (ICP-MS), wherein f) optionally comprises cleaving the one or more biomolecules in said sample wherein, said cleaving may be performed (i) before coupling of the reagent PRG or (ii) after coupling.07-01-2010
20100221699AMINE-N-OXIDE REDOX INDICATORS FOR FLUORIMETRIC DETERMINATION OF ANALYTES - A reagent for detecting an analyte by a redox reaction and a fluorimetric determination is disclosed. The reagent comprises a compound of formula (I):09-02-2010
20090092960Novel Fluorescent and Colored Proteins, and Polynucleotides that Encode These Proteins - The subject invention provides new fluorescent and/or colored proteins, and polynucleotide sequences that encode these proteins. The subject invention further provides materials and methods useful for expressing these detectable proteins in biological systems.04-09-2009
20100267004Method, Substances and Kits for Labeling Population of RNA and Other Substances Containing Vicinal Diols - A method for labeling biological molecules and synthetic molecules that contain a geminal diol, such as RNA, carbohydrates or glycoproteins, using a periodate sequestering agent is provided. Compositions and kits for use in the labeling method are also provided.10-21-2010
20120040332ASSAY FOR DETECTION OF ADRENAL TUMOUR - The invention relates to methods, assays and kits for detecting or monitoring adrenal tumours by detecting one or more adrenal steroid metabolites. The metabolites are selected from THS (tetrahydro-11-desoxycortisol), 5-PT (5-pregnenetriol), 5-PD (pregnenediol), PD (pregnanediol), PT (pregnanetriol), Et (etiolanolone), TH-DOC (tetrahydro-11-corticosterone), (5α-THA) 5α-tetra-11-hydrocorticosterone, and 5α-THF (5α-tetra hydrocortisol. An (Androsterone) may also be measured. 6β-OH-cortisol may be measured to monitor mitotane therapy.02-16-2012
20120040333Methods to Distinguish Different Disaccharide Products after Digestion with Heparinases - Methods are provided for determining stereochemistry for a component of a composition where the composition includes a glycosaminoglycan (GAG) where the method includes (a) cleaving the GAG with a lyase; (b) separating the products of the cleaved GAG by chromatography in the presence of one or more solvents wherein at least one solvent comprises an organic acid or organic acid derivative in an amount of no more than 50% v/v of solvent; and determining the stereochemistry of the component.02-16-2012
20120301870Enhanced Stability of Proteins Immobilized on Nanoparticles - This invention is directed to the application of a previously unknown property of nanomaterials—its ability to enhance protein activity and stability at high temperatures, in organic solvents, and in polymer composites. Nanomaterials such as single-walled carbon nanotubes (SWNTs) can significantly enhance enzyme function and stability in strongly denaturing environments. Experimental results and theoretical analysis reveal that the enhancement in stability is a result of the curvature of these nanoscale materials, which suppresses unfavorable protein-protein interactions.11-29-2012
20090215025SMALL PEPTIDIC AND PEPTIDO-MIMETIC AFFINITY LIGANDS FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - The present invention pertains to compounds that show a high affinity to Factor VIII and Factor VIII-like proteins, and their uses. The compounds are characterized by the general Formula B-Q-X, wherein B represents a dipeptide, tripeptide, or a peptidomimetic; Q represents a spacer and X represents an anchoring molecule; Q and X are optional. These compounds can be used for coating a solid support material. The resulting coated solid support material can be used for purifying Factor VIII by means of affinity chromatography methods. In addition, the compounds of the present invention may be used for stabilizing Factor VIII and for enhancing its activity. The present invention thus pertains also to methods for manufacturing a stabilized Factor VIII containing medicament of increased activity. The inventive compounds can furthermore be used in diagnostic kits and as research tools.08-27-2009
20110318726PREDICTING CORONARY ARTERY DISEASE AND RISK OF CARDIOVASCULAR EVENTS - Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease.12-29-2011
20100267003METHODS AND KIT FOR ENDOMETRIOSIS SCREENING - Methods of screening a bodily sample for endometriosis are provided. The bodily sample is preferably saliva. According to one embodied method, the bodily sample is subjected to a denaturing procedure, and a property of the bodily sample observed after the denaturing procedure is evaluated for the presence or absence of a factor correlating to endometriosis as part of an endometriosis screening procedure. The methods embodied herein are preferably conducted in combinations which permit for the evaluation of at least two different physiological factors correlating to endometriosis, because women with endometriosis do not always share the same factors. Also provided are screening kits, assay methods, and systems for endometriosis screening.10-21-2010
20120208173TERPENE SYNTHASES FROM SANTALUM - An isolated nucleic acid molecule that encodes a terpene synthase and is selected from among: a) a nucleic acid molecule comprising the sequence of nucleotides set forth in SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5; b) a nucleic acid molecule that is a fragment of (a); c) a nucleic acid molecule comprising a sequence of nucleotides that is complementary to (a)- or (b); and d) a nucleic acid molecule that encodes a terpene synthase having at least or at least about or at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity to any one of (a)-(c); wherein the nucleic acid molecule encodes a terpene synthase.08-16-2012
20090029345MODULATING SKELETAL MUSCLE - Methods of identifying skeletal muscle activators are provided. Methods of activating skeletal muscle using skeletal muscle activators are also provided.01-29-2009
20100221698In-Vitro Deposition Evaluation Method for Identifying Personal Care Compositions Which Provide Improved Deposition of Benefit Agents - The present invention relates to an in-vitro deposition evaluation method and an system for evaluating deposition of personal care compositions. The method comprises the steps of providing a microplate and at least one body that is capable of movement within the plurality of wells of the microplate. The method comprises the steps of providing a sample that comprises a personal care composition and depositing sufficient volume of sample to submerge a body within the wells of the microplate. The method comprises the steps of providing a skin mimic and contacting the skin mimic and the microplate such that the skin mimic is exposed to the sample and the body. The method comprises the steps of causing at least one body to move wherein a portion of the sample is transferred to the skin mimic and quantifying the amount of the sample that is transferred to the skin mimic.09-02-2010
20090253118LUMINESCENCE QUENCHERS AND FLUOROGENIC PROBES FOR DETECTION OF REACTIVE SPECIES - Provided herein are compounds or fluorogenic probes which can be used as reagents for measuring, detecting and/or screening ROS or RNS such as peroxynitrite or hypochlorite. Provided also herein are methods that can be used to measure, directly or indirectly, the amount of peroxynitrite or hypochlorite in chemical samples and biological samples such as cells and tissues in living organisms. Specifically, the methods include the steps of contacting the fluorogenic probes disclosed herein with the samples to form one or more fluorescent compounds, and measuring fluorescence properties of the fluorescent compounds. Provided also herein are high-throughput screening fluorescent methods for detecting or screening peroxynitrite or compounds that can increase or decrease the level of peroxynitrite or hypochlorite in chemical and biological samples.10-08-2009
20110091864Device And Use Thereof - Disclosed herein is a device comprising at least one supporting solid surface comprising at least one membraneophilic region; a covering layer that is at least partially immobilized to the membraneophilic region, said covering layer consisting of (i) a surfactant membrane, (ii) a lipid mimicking polymer, (iii) a surfactant or emulsion system or (iv) a liquid crystal; and a substance included in or bound to, connected to or associated with the covering layer. Also disclosed are methods wherein the device is used and use of the device.04-21-2011
20120122077Method to Detect and Sequence Post Translationally Modified Peptides - A method of detecting and sequencing post translationally modified peptides is disclosed wherein a negative ion precursor scan is performed. A negative ion high resolution MS scan is then performed and then MRM channels in positive ion mode are determined and monitored. A positive ion MS/MS scan is then performed.05-17-2012
20120122076PURIFICATION OF ANTIBODIES USING SIMULATED MOVING BED CHROMATOGRAPHY - The present invention relates to compositions and methods for the chromatographic purification of antibodies, such as monoclonal antibodies, employing improved simulated moving bed separation strategies and, in certain embodiments, Raman spectroscopy.05-17-2012
20090130648Oxidized Phospholipids - The invention relates to oxidized phospholipids having one of the general formulas (I) or (II) wherein A=O, C, NH, or S; B═O, C, NH, or S; and R05-21-2009
20120129150PARTICLES EMBEDDED IN A POROUS SUBSTRATE FOR REMOVING TARGET ANALYTE FROM A SAMPLE - The invention provides devices, test kits and methods for removing target agents from a sample. The device contains one or more porous matrices having pore sizes larger than 05-24-2012
20100273142MULTI-COMPARTMENT DEVICE WITH MAGNETIC PARTICLES - The present invention discloses microfluidic devices with a valve-like structure (3), through which magnetic particles can be transported with minimal transport of fluids. This allows sequential processing of the magnetic particles.10-28-2010
20090061411ANALYSIS OF SULFATED POLYSACCHARIDES - The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.03-05-2009
20100291536SAMPLE PROCESSING CASSETTE, SYSTEM, AND METHOD - The present invention provides a method and device for collecting treating and analysis of biological or chemical material by introducing a source material into a specimen container, transferring the source material to a processing device and thermally, chemically and/or mechanically treating the source material to alter at least one constitutive characteristic of the source material and to release or create a target material from the source material.11-18-2010
20110123976Biomarkers and identification methods for the early detection and recurrence prediction of breast cancer using NMR - A method is provided for the parallel identification of one or more metabolite species within a biological sample. The method comprises analyzing the sample to produce a spectrum containing individual spectral peaks representative of the one or more metabolite species contained within the sample; subjecting each of the individual spectral peaks to a statistical pattern recognition analysis to identify the one or more metabolite species contained within the sample; and identifying the one or more metabolite species contained within the sample by analyzing the individual spectral peaks of the spectra.05-26-2011
20100304357UNIVERSAL DRINKING ADAPTER FOR BEVERAGE BOTTLES, AND DEVICES AND KITS FOR DETERMINING SMALL MOLECULES, METAL IONS, ENDOTOXINS, AND BACTERIA, AND METHODS OF USE THEREOF - Certain features, aspects, examples and embodiments described herein relate to adapters for securing drinking apparatuses for individuals of all ages (infants, children, adults, and seniors) such as nipples, sippers, and straws, to commercially available beverage containers to aid in the consumption of the contained liquid. Other features, aspects, examples and embodiments relate to devices and kits useful for the detection of analytes in milk samples such as small molecules, metal ions, endotoxins, and bacteria.12-02-2010
20080299543Method for Assessing Trace Element Related Disorders in Blood Plasma - The present invention provides for spectrometric methods of analyzing plasma or serum for metal distribution in metalloproteins. The methods can be used to assess such conditions as toxicity and disease in subjects.12-04-2008
20080299542IDENTIFICATION OF OXIDATIVELY MODIFIED PEPTIDE SEQUENCES IN THE PROTEOME (LOSCALZO) - The invention relates, in part, to identifying protein target(s) that undergo oxidative modification and the specific peptide sequences bearing oxidation-induced modifications.12-04-2008
20080299541METHOD AND APPARATUS FOR MEASURING ENZYMATIC ACTIVITY BY USE OF LASER - A method of measuring an enzymatic activity, includes measuring the quantity of a substrate metabolite produced upon metabolism of a substrate by an enzyme, through detecting a radiant wave generated from a multiple photon excitation process of the substrate or the substrate metabolite.12-04-2008
20080299540Hormone responsive tissue culture system and uses thereof - The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate.12-04-2008
20100055665LUMINESCENCE ASSAY USING MACROCYCLIC LANTHANIDE (III) COMPLEXES - The invention provides a method of determining the amount of an analyte having an oxidation potential, for a one electron oxidation process, of about +0.10 to about +1.20 volts at pH 7, relative to the normal hydrogen electrode at 298K, said method comprising measuring the emission intensity or emission lifetime, at two or more wavelengths, from a sample comprising said analyte and two or more different macrocyclic lanthanide (III) complexes, wherein each of said macrocyclic lanthanide (III) complexes comprises a different lanthanide ion but the same macrocyclic ligand, and using a ratio of emission intensities or emission lifetimes measured at two different wavelengths to calculate the amount of analyte in said sample.03-04-2010
20100203495PROCESSING BIOMASS - Biomass feedstocks (e.g., plant biomass, animal biomass, and municipal waste biomass) are processed to produce useful products, such as fuels. For example, systems are described that can use feedstock materials, such as cellulosic and/or lignocellulosic materials and/or starchy materials, to produce a product or intermediate, e.g., energy, a food, a fuel, or a material.08-12-2010
20090176199METHOD OF ISOTOPE LABELING AND DETERMINING PROTEIN SYNTHESIS, QUANTITATION AND PROTEIN EXPRESSION - A method including isotope labeling of a newly synthesized protein in a sufficient quantity such that a newly synthesized protein spectra and the pre-existing protein spectra are sufficiently separated. A further method including determining a ratio of a new and a pre-existing protein from mass spectra obtained by using mass spectrometry. In this method a resultant spectrum may be presented as integrated peak heights for a corresponding mass to charge ratio in the “centroid” mode.07-09-2009
20090269731E3-INDEPENDENT UBIQUITINYLATION ASSAY - Disclosed herein are compositions and methods for assaying ubiquitination independent of ubiquitin ligase (E3) or a target protein.10-29-2009
20090263784THREE-DIMENSIONAL STRUCTURE OF PROSTAGLANDIN D SYNTHASE AND UTILIZATION THEREOF - A method of designing an anti-allergic agent, sleep controlling agent, anti-obesity agent and remedy for brain injury acting via the inhibition of biosynthesis of prostaglandin D10-22-2009
20110159476METHODS AND APPARATUS FOR CHARACTERIZING POLYMERIC MIXTURES - The invention provides methods and apparatus for characterizing complex polymeric mixture of interest. Candidate solutions are eliminated from a solution space using one or more experimental measurements of a polymeric mixture of interest. The elimination step can be repeated one or more times using different experimental measurements produced by various chemical and physical protocols, so that the remaining candidate solutions converge to describe the actual polymeric mixture under investigation. Once the composition of the complex polymeric mixture has been characterized, the information thus generated can be used to facilitate, for example, the manufacture of a bio-equivalent of the complex polymeric mixture.06-30-2011
20080241816Method for Stabilizing Oxidizable Color Developing Reagent - A method of storing/stabilizing an oxidizable color-assuming reagent, especially a leuco dye; and a stabilized reagent obtained thereby. The method of stabilizing an oxidizable color-assuming reagent comprises storing the oxidizable color-assuming reagent in a solution having a pH of 1 to 5.10-02-2008
20080233556CYTOTONIC PROTEIN AND UTLIZATION THEREOF - This invention relates to a new cytotoxic protein (M toxin, mucous layer devastating toxin) produced by 09-25-2008
20130143201Crystallographic structure of TcPRACA and uses therefor - A method of identifying a substance that affects the biological activity of a 06-06-2013
20080220407Fluorescent water-soluble conjugated polyene compounds that exhibit aggregation induced emission and methods of making and using same - The presently described subject matter is directed to water-soluble conjugated polyene compounds that exhibit aggregation induced emission, as well as to water dispersible, fluorescent, polymeric microparticles and/or nanoparticles comprising the water-soluble conjugated polyene compounds. Also provided are methods of making and using the compounds and particles. The described conjugated polyene compounds are useful as bioprobes for the detection biomacromolecules, as well as in the manufacture of sensors.09-11-2008
20080311554Methods for monitoring patients with severe sepsis and septic shock and for selecting treatments for these patients - Methods of identifying, monitoring and matching patients with appropriate treatments who are at risk for developing a systemic inflammatory condition using a systemic mediator-associated physiologic test profile are provided. The methods of the present invention increase the likelihood of demonstrating clinical efficacy in clinical trial datasets.12-18-2008
20090092961IDENTIFICATION AND MODIFICATION OF DYNAMICAL REGIONS IN PROTEINS FOR ALTERATION OF ENZYME CATALYTIC EFFECT - A method for analysis, control, and manipulation for improvement of the chemical reaction rate of a protein-mediated reaction is provided. Enzymes, which typically comprise protein molecules, are very efficient catalysts that enhance chemical reaction rates by many orders of magnitude. Enzymes are widely used for a number of functions in chemical, biochemical, pharmaceutical, and other purposes. The method identifies key protein vibration modes that control the chemical reaction rate of the protein-mediated reaction, providing identification of the factors that enable the enzymes to achieve the high rate of reaction enhancement. By controlling these factors, the function of enzymes may be modulated, i.e., the activity can either be increased for faster enzyme reaction or it can be decreased when a slower enzyme is desired. This method provides an inexpensive and efficient solution by utilizing computer simulations, in combination with available experimental data, to build suitable models and investigate the enzyme activity.04-09-2009
20130130230PROTEIN-ENCLOSED CARBON NANOTUBE FILM, AND SENSOR AND POWER-GENERATING DEVICE EACH EQUIPPED WITH THE CARBON NANOTUBE FILM AS ELECTRODE - The present invention answers the demands of power generating device and biosensor development and provides a flexible, free-standing type protein containing carbon nanotube film, and a sensor and power generating device each equipped with the carbon nanotube film as an electrode. According to the present invention a carbon nanotube free standing film is provided including a carbon nanotube aggregate formed by aggregating a plurality of carbon nanotubes, and a plurality of enzymes included between the plurality of carbon nanotubes. The carbon nanotube film may include a different protein to the enzyme and may include a surfactant agent between the plurality of carbon nanotubes.05-23-2013
20080199850Egfr Dependent Modulation of Chemokine Expression and Influence on Therapy and Diagnosis of Tumors and Side Effects Thereof - The invention relates to diagnosis and therapy of tumors utilizinging the epidermal growth factor (EGFR) by means of chemical inhibitors or monoclonal antibodies. The invention relates also to skin irritations, preferably skin rash, in conjunction and associated with the treatment of tumor cells that utilize EGF receptor with anti-cancer agents. The invention is also directed to methods of predicting the efficiency of a tumor therapy/tumor response in a patient based on the treatment with EGFR inhibitors, especially anti-EGFR antibodies. The invention further relates to a method of determining the optimum dose of an anti-cancer agent in EGFR related tumor therapy.08-21-2008
20080199848Method For Determining the Concentration of Asymmetric Dimethylarginine (Adma) - The invention relates to a method for determining the concentration of asymmetric dimethylarginine (ADMA) simultaneously with arginine and with symmetric dimethylarginine (SDMA) in biological samples by means of HPLC-MS-MS. The sample preparation consists exclusively of adding a solution of isotope-labeled internal standards (08-21-2008
20110236878Rapid Characterization of Proteins in Complex Biological Fluids - Disclosed herein are compositions and methods for the rapid screening of candidate protein therapeutics. In particular, the instant invention provides compositions and methods for assaying the behavior of candidate protein therapeutics in complex biological fluids and for identifying those candidate protein therapeutics exhibiting desirable pharmacokinetic properties in such fluids.09-29-2011
20110275057ALLOSTERIC CONTROL OF PROTEINS BY MANIPULATING MECHANICAL TENSION - A method of altering the conformation of a polypeptide having a known three-dimensional structure is described. The method comprises attaching a first end of a polymer to a first portion of the polypeptide, attaching a second end of the polymer to a second portion of the polypeptide, and altering the mechanical tension of the polymer, thereby altering the conformation of the polypeptide. The alteration of the conformation of the polypeptide may increase or decrease the binding affinity of the polypeptide for a substrate bound by the polypeptide, or alter the catalytic rate of an enzyme. Typically, the polymer is a polynucleotide or polypeptide.11-10-2011
20120282592BIOMARKER OF DEPRESSION, METHOD FOR MEASURING BIOMARKER OF DEPRESSION, COMPUTER PROGRAM, AND RECORDING MEDIUM - Provided is a method for using low molecular weight compounds found in the body as a biomarker for diagnosing depression. Specifically, more than one compound selected from a group comprising the following are used: ADP-ribose, ATP, ADP, AMP, serotonin, tryptophan, kynurenine, SDMA (symmetrical dimethylarginine), threonine, glyceric acid, serine, N-acetylaspartic acid, glutamic acid, trigonelline, creatine, 2-methylserine, sphingosine, homovanillic acid, piperidine, sulfoxidized methionine, pipecolic acid, sphinganine, gamma-butyrobetaine, guanidinoacetic acid, isobutyric acid, creatinine, sarcosine, 3-methylbutyric acid, nicotinamide, betaine, ornithine, carnitine, ethanolamine, phosphoethanolamine, taurine, hypotaurine, aspartic acid, methionine, and tyrosine.11-08-2012
20130157251IN SITU-DILUTION METHOD AND SYSTEM FOR MEASURING MOLECULAR AND CHEMICAL INTERACTIONS - The present invention relates to a method for testing multiple analyte concentrations within a biosensor system through a single injection of sample. The method involves flowing a fluid sample containing a neat analyte concentration along a flow path in a fluid system and diluting the sample by causing it to merge with a fluid that is free of analyte in a second flow path under laminar flow conditions. The merged fluid stream is directed through a turbulent third flow path of a very low dead volume. The third flow path carries the merged fluid stream to a sensing region where the analyte is exposed to an immobilized ligand. The concentration of analyte can be controlled in this method by adjusting the flow rates of the sample flow and analyte-free fluid flow. A fluidic system for carrying out this method is also disclosed.06-20-2013
20130157252DIAGNOSTIC MARKER FOR KIDNEY DISEASES AND USE THEREOF - The present invention relates to novel diagnostic markers for kidney disease and the use thereof.06-20-2013
20090047655Method Of Screening Candidate Drug - It is intended to provide a method of screening a candidate drug mainly metabolized by a drug metabolizing enzyme, CYP2D6, CYP2C9 or CYP2C19 with the use of a chimeric mouse carrying human hepatocytes transplanted thereinto, whereby it is determined whether or not the candidate drug is metabolized in a subject deficient in CYP2D6, CYP2C9 or CYP2C19. It is also intended to provide a method of determining whether or not a candidate drug induces or inhibits the activity of any of drug metabolizing enzymes, CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 with the use of a chimeric mouse carrying human hepatocytes transplanted thereinto.02-19-2009